These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 39159716)

  • 1. CB-839 induces reversible dormancy in lung tumor-cells.
    Jamshidi-Parsian A; Jenkins SV; Tran A; Bragg A; Davis R; Griffin C; Siegel E; Dings RPM; Griffin RJ; Boysen G
    Eur J Pharmacol; 2024 Nov; 982():176912. PubMed ID: 39159716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
    Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
    Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
    BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
    Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
    Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.
    Boysen G; Jamshidi-Parsian A; Davis MA; Siegel ER; Simecka CM; Kore RA; Dings RPM; Griffin RJ
    Int J Radiat Biol; 2019 Apr; 95(4):436-442. PubMed ID: 30557074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
    Cheng ZJ; Miao DL; Su QY; Tang XL; Wang XL; Deng LB; Shi HD; Xin HB
    Acta Pharmacol Sin; 2019 Jun; 40(6):814-822. PubMed ID: 30446732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
    Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
    Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of anti-tumor effect and mechanism of GLS1 inhibitor CB-839 in colorectal cancer using a stroma-abundant tumor model.
    Miyamoto R; Takigawa H; Yuge R; Shimizu D; Ariyoshi M; Otani R; Tsuboi A; Tanaka H; Yamashita K; Hiyama Y; Urabe Y; Ishikawa A; Sentani K; Oka S
    Exp Mol Pathol; 2024 Jun; 137():104896. PubMed ID: 38703552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
    Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
    Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
    Reis LMD; Adamoski D; Ornitz Oliveira Souza R; Rodrigues Ascenção CF; Sousa de Oliveira KR; Corrêa-da-Silva F; Malta de Sá Patroni F; Meira Dias M; Consonni SR; Mendes de Moraes-Vieira PM; Silber AM; Dias SMG
    J Biol Chem; 2019 Jun; 294(24):9342-9357. PubMed ID: 31040181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
    Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
    J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells.
    Peyton KJ; Liu XM; Yu Y; Yates B; Behnammanesh G; Durante W
    Biochem Pharmacol; 2018 Oct; 156():204-214. PubMed ID: 30144404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of glutamine metabolism in acquired-EGFR-TKI-resistant lung cancer.
    Kim S; Jeon JS; Choi YJ; Baek GH; Kim SK; Kang KW
    Life Sci; 2022 Feb; 291():120274. PubMed ID: 34990648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
    Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
    PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous inhibition of PFKFB3 and GLS1 selectively kills KRAS-transformed pancreatic cells.
    Ozcan SC; Mutlu A; Altunok TH; Gurpinar Y; Sarioglu A; Guler S; Muchut RJ; Iglesias AA; Celikler S; Campbell PM; Yalcin A
    Biochem Biophys Res Commun; 2021 Sep; 571():118-124. PubMed ID: 34325126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
    Thompson RM; Dytfeld D; Reyes L; Robinson RM; Smith B; Manevich Y; Jakubowiak A; Komarnicki M; Przybylowicz-Chalecka A; Szczepaniak T; Mitra AK; Van Ness BG; Luczak M; Dolloff NG
    Oncotarget; 2017 May; 8(22):35863-35876. PubMed ID: 28415782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.
    Momcilovic M; Bailey ST; Lee JT; Fishbein MC; Magyar C; Braas D; Graeber T; Jackson NJ; Czernin J; Emberley E; Gross M; Janes J; Mackinnon A; Pan A; Rodriguez M; Works M; Zhang W; Parlati F; Demo S; Garon E; Krysan K; Walser TC; Dubinett SM; Sadeghi S; Christofk HR; Shackelford DB
    Cell Rep; 2017 Jan; 18(3):601-610. PubMed ID: 28099841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.
    Chen Y; Zhao Y; Bajor DL; Wang Z; Selfridge JE
    J Genet Genomics; 2020 Jul; 47(7):389-395. PubMed ID: 33004309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutaminase 1 plays critical roles in myelodysplastic syndrome and acute myeloid leukemia cells.
    Okabe S; Moriyama M; Arai Y; Gotoh A
    Cancer Biomark; 2024; 41(1):55-68. PubMed ID: 39213050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
    Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
    Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.